A detailed history of Platform Technology Partners transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Platform Technology Partners holds 2,462 shares of SRPT stock, worth $272,051. This represents 0.1% of its overall portfolio holdings.

Number of Shares
2,462
Previous 2,137 15.21%
Holding current value
$272,051
Previous $337,000 8.9%
% of portfolio
0.1%
Previous 0.12%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 04, 2024

BUY
$124.33 - $156.75 $40,407 - $50,943
325 Added 15.21%
2,462 $307,000
Q4 2023

Feb 13, 2024

SELL
$67.31 - $124.76 $66,502 - $123,262
-988 Reduced 31.62%
2,137 $206,000
Q3 2023

Nov 08, 2023

SELL
$102.5 - $123.59 $15,375 - $18,538
-150 Reduced 4.58%
3,125 $378,000
Q2 2023

Jul 12, 2023

BUY
$106.4 - $157.19 $1,276 - $1,886
12 Added 0.37%
3,275 $375,000
Q1 2023

Apr 04, 2023

BUY
$117.53 - $155.99 $24,446 - $32,445
208 Added 6.81%
3,263 $449,000
Q3 2022

Oct 24, 2022

SELL
$75.71 - $119.24 $26,725 - $42,091
-353 Reduced 10.36%
3,055 $338,000
Q2 2022

Aug 04, 2022

BUY
$62.69 - $88.44 $188 - $265
3 Added 0.09%
3,408 $255,000
Q3 2021

Nov 04, 2021

SELL
$65.97 - $92.48 $60,692 - $85,081
-920 Reduced 21.27%
3,405 $315,000
Q2 2021

Aug 05, 2021

BUY
$69.38 - $86.75 $2,428 - $3,036
35 Added 0.82%
4,325 $336,000
Q4 2020

Feb 09, 2021

SELL
$125.56 - $178.74 $31,390 - $44,685
-250 Reduced 5.51%
4,290 $731,000
Q3 2020

Nov 30, 2020

BUY
$127.12 - $172.34 $92,797 - $125,808
730 Added 19.16%
4,540 $638,000
Q2 2020

Nov 30, 2020

SELL
$93.0 - $171.7 $78,585 - $145,086
-845 Reduced 18.15%
3,810 $611,000
Q1 2020

Nov 30, 2020

SELL
$82.38 - $131.64 $278,444 - $444,943
-3,380 Reduced 42.07%
4,655 $455,000
Q4 2019

Dec 03, 2020

BUY
$76.53 - $135.58 $614,918 - $1.09 Million
8,035 New
8,035 $1.04 Million

Others Institutions Holding SRPT

About Sarepta Therapeutics, Inc.


  • Ticker SRPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 87,567,904
  • Market Cap $9.68B
  • Description
  • Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...
More about SRPT
Track This Portfolio

Track Platform Technology Partners Portfolio

Follow Platform Technology Partners and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Platform Technology Partners, based on Form 13F filings with the SEC.

News

Stay updated on Platform Technology Partners with notifications on news.